BioNTech SE Share Price Xetra
Equities
US09075V1026
Biotechnology & Medical Research
Sales 2024 * | 2.75B 2.93B 245B | Sales 2025 * | 2.74B 2.93B 245B | Capitalization | 19.12B 20.44B 1,708B |
---|---|---|---|---|---|
Net income 2024 * | -419M -448M -37.44B | Net income 2025 * | -548M -586M -48.96B | EV / Sales 2024 * | 2.35 x |
Net cash position 2024 * | 12.67B 13.55B 1,132B | Net cash position 2025 * | 12.02B 12.85B 1,074B | EV / Sales 2025 * | 2.59 x |
P/E ratio 2024 * |
-43.8
x | P/E ratio 2025 * |
-34.7
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.48% |
Latest transcript on BioNTech SE
Managers | Title | Age | Since |
---|---|---|---|
Ugur Sahin
CEO | Chief Executive Officer | 58 | 02/08/02 |
Özlem Türeci
FOU | Founder | 57 | 02/08/02 |
Jens Holstein
DFI | Director of Finance/CFO | 60 | 01/21/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Rudolf Staudigl
BRD | Director/Board Member | 70 | 01/22/01 |
Director/Board Member | 67 | 02/08/02 | |
Helmut Jeggle
CHM | Chairman | 53 | 02/08/02 |
1st Jan change | Capi. | |
---|---|---|
+15.19% | 121B | |
+19.91% | 114B | |
+8.24% | 23.61B | |
-16.19% | 16.55B | |
-13.45% | 16.45B | |
-44.35% | 15.59B | |
+66.67% | 15.19B | |
+2.13% | 13.54B | |
+119.39% | 10.96B |